Literature DB >> 17221844

Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis.

Marianne A Mihalyo1, Adam T Hagymasi, Aaron M Slaiby, Erin E Nevius, Adam J Adler.   

Abstract

BACKGROUND: Prostate cancer promotes the development of T cell tolerance towards prostatic antigens, potentially limiting the efficacy of prostate cancer vaccines targeting these antigens. Here, we sought to determine the stage of disease progression when T cell tolerance develops, as well as the role of steady state dendritic cells (DC) and CD4(+)CD25(+) T regulatory cells (Tregs) in programming tolerance.
METHODS: The response of naïve HA-specific CD4(+) T cells were analyzed following adoptive transfer into Pro-HA x TRAMP transgenic mice harboring variably-staged HA-expressing prostate tumors on two genetic backgrounds that display different patterns and kinetics of tumorigenesis. The role of DC and Tregs in programming HA-specific CD4 cell responses were assessed via depletion.
RESULTS: HA-specific CD4 cells underwent non-immunogenic responses at all stages of tumorigenesis in both genetic backgrounds. These responses were completely dependent on DC, but not appreciably influenced by Tregs.
CONCLUSIONS: These results suggest that tolerogenicity is an early and general property of prostate tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17221844      PMCID: PMC2846359          DOI: 10.1002/pros.20549

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  46 in total

1.  CD4 cell priming and tolerization are differentially programmed by APCs upon initial engagement.

Authors:  Amy D Higgins; Marianne A Mihalyo; Patrick W McGary; Adam J Adler
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

2.  Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo.

Authors:  C Kurts; M Cannarile; I Klebba; T Brocker
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

3.  Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells.

Authors:  Takekazu Kubo; Robin D Hatton; James Oliver; Xiaofen Liu; Charles O Elson; Casey T Weaver
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

4.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

Authors:  Charles G Drake; Amy D H Doody; Marianne A Mihalyo; Ching-Tai Huang; Erin Kelleher; Sowmya Ravi; Edward L Hipkiss; Dallas B Flies; Eugene P Kennedy; Meixiao Long; Patrick W McGary; Lee Coryell; William G Nelson; Drew M Pardoll; Adam J Adler
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

5.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

6.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

Authors:  Tyler J Curiel; George Coukos; Linhua Zou; Xavier Alvarez; Pui Cheng; Peter Mottram; Melina Evdemon-Hogan; Jose R Conejo-Garcia; Lin Zhang; Matthew Burow; Yun Zhu; Shuang Wei; Ilona Kryczek; Ben Daniel; Alan Gordon; Leann Myers; Andrew Lackner; Mary L Disis; Keith L Knutson; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

7.  CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells.

Authors:  A J Adler; D W Marsh; G S Yochum; J L Guzzo; A Nigam; W G Nelson; D M Pardoll
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

8.  An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues.

Authors:  J Hu; W Kindsvogel; S Busby; M C Bailey; Y Y Shi; P D Greenberg
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

9.  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.

Authors:  Ping Yu; Youjin Lee; Wenhua Liu; Thomas Krausz; Anita Chong; Hans Schreiber; Yang-Xin Fu
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

10.  Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node.

Authors:  Clemens Scheinecker; Rebecca McHugh; Ethan M Shevach; Ronald N Germain
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

View more
  15 in total

1.  Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells.

Authors:  Adam T Hagymasi; Aaron M Slaiby; Marianne A Mihalyo; Harry Z Qui; David J Zammit; Leo Lefrancois; Adam J Adler
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

Review 2.  Regulatory considerations for clinical development of cancer vaccines.

Authors:  Bridget Theresa Heelan
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.

Authors:  Adam J Adler; Payal Mittal; Joseph M Ryan; Beiyan Zhou; Jeffrey S Wasser; Anthony T Vella
Journal:  Immunotherapy       Date:  2017-01       Impact factor: 4.196

4.  Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.

Authors:  Tullia C Bruno; Cristin Rothwell; Joseph F Grosso; Derese Getnet; Hung Rong Yen; Nicholas M Durham; George Netto; Drew M Pardoll; Charles G Drake
Journal:  Prostate       Date:  2011-07-14       Impact factor: 4.104

Review 5.  Prostate cancer as a model for tumour immunotherapy.

Authors:  Charles G Drake
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

6.  In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.

Authors:  Elizabeth J Akins; Miranda L Moore; Shuai Tang; Mark C Willingham; Janet A Tooze; Purnima Dubey
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

7.  Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.

Authors:  Timothy J Harris; Edward L Hipkiss; Scott Borzillary; Satoshi Wada; Joseph F Grosso; Hung-Rong Yen; Derese Getnet; Tullia C Bruno; Monica V Goldberg; Drew M Pardoll; Theodore L DeWeese; Charles G Drake
Journal:  Prostate       Date:  2008-09-01       Impact factor: 4.104

8.  Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses.

Authors:  Michael Y Gerner; Kerry A Casey; Matthew F Mescher
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.

Authors:  Moniek A de Witte; Gavin M Bendle; Marly D van den Boom; Miriam Coccoris; Todd D Schell; Satvir S Tevethia; Harm van Tinteren; Elly M Mesman; Ji-Ying Song; Ton N M Schumacher
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

10.  Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.

Authors:  Derese Getnet; Charles H Maris; Edward L Hipkiss; Joseph F Grosso; Timothy J Harris; Hung-Rong Yen; Tullia C Bruno; Satoshi Wada; Adam Adler; Robert W Georgantas; Chunfa Jie; Monica V Goldberg; Drew M Pardoll; Charles G Drake
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.